Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.

You may also be interested in...



Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?

The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.

Academic Drug-Discovery Units Team Up To Share Knowledge, Facilitate Partnering

Founded in 2012, the Academic Drug Discovery Consortium intends to serve as a clearinghouse for both academia and industry on research underway at U.S. and international drug research programs. It won’t undertake tech transfer work itself, but the ADDC hopes to make it easier for academics and biopharma to work together.

AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013

Between 2010 and the first quarter of 2013, biopharma engaged in 70 deals involving neurodegenerative disease assets covering a wide variety of targets – possibly a consequence of uncertainty about the underlying pathophysiology. AstraZeneca was the top deal maker in the field even as it moved away from CNS as a core therapeutic area.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel